|
08 August 2011: New Appointments at CM&D Pharma Limited
A new Group Finance Director and Business Development Manager reflect new phase of growth for CM&D
25 July 2011: Eviendep™ Data Accepted As Oral Presentation at UEGW
Pivotal Eviendep Clinical Trial Results to be Presented at 19th United European Gastroenterology Week, Stockholm, October 22-26, 2011.
21 February 2011: Dr Geoffrey Block, MD, Appointed to CM&D Advisory Board
Leading US nephrologist appointed to Advisory Board to enhance its clinical strength.
02 February 2011: Acquisition of CM&D Pharma Limited by Nestlé
Founder welcomes a new era for CM&D Pharma following its acquisition by Nestlé SA
04 February 2010: Fostrap(TM) Clinical Trials Under Way in Japan and the USA
CM&D Pharma Limited's innovative therapy for hyperphosphatemia, Fostrap, is being tested in two pivotal clinical studies
06 November 2009: Ossulin(TM) Shows Promising Bioavailability
Data presented shows the novel oral insulin product consistently delivers around 20% of insulin into bloodstream.
19 June 2009: Fostrap Partner for Japan Announced
CM&D has announced its first development agreement for its major new product, Fostrap.
09 March 2009: CM&D Pharma Acquires Biohealth Italia srl
CM&D on course for rapid expansion - first of five corporate acquisitions in EU planned over 2 years.
26 February 2009: New study shows Fostrap helps treat high phosphate levels in kidney disease patients
New product from CM&D Pharma Limited shows positive results.
23 February 2009: Richard Meek Appointed Group Finance Director of CM&D Pharma Limited
Experience in the development of growth businesses and M&A major factors in appointment
15 July 2008: Denise Ström Appointed to CM&D Pharma Scientific Board
As CM&D steps up its clinical and regulatory development, Denise Ström is a key appointment
31 March 2008: Prof. Antonio Tiengo Appointed to CM&D Pharma Scientific Board
The Scientific Board of CM&D Pharma is boosted by the appointment of a leading expert in metabolic diseases.
20 March 2008: Dr Nadia Peviani, CEO of Temas, Appointed to CM&D Advisory Board
CM&D Pharma Limited further strengthens its Advisory Board by adding a leader in the field of European regulatory affairs, Dr Nadia Peviani
11 March 2008: CM&D Pharma Incorporates R&D Headquarters in Italy
CM&D Pharma Srl will drive the R&D programme of both CM&D and Puredel Ltd from its base in Padova.
16 January 2008: CM&D Pharma Appoints Dr Marco Prosdocimi to Scientific Board
Leading pharmacologist Dr Marco Prosdocimi will strengthen CM&D's R&D team following product acquisitions
16 January 2008: Dr Cosimo Pulli, General Manager of Chiesi Pharma Italy, is Appointed to CM&D Pharma’s Advisory Board
Senior pharma executive Dr Pulli of Chiesi Farmaceutici joins CM&D's Advisory Board
16 January 2008: Dr Giorgio Pisani, President and CEO, IBSA Farmaceutici Italia, is Appointed to CM&D Pharma’s Advisory Board
IBSA Director Dr Giorgio Pisani strengthens CM&D's Advisory Board
16 January 2008: CM&D Pharma Appoints Dr Paolo Rampazzo to Scientific Board
Scientific Board welcomes Dr Paolo Rampazzo to CM&D Pharma
16 January 2008: CM&D acquires rights to Fostrap™ for the treatment of hyperphosphataemia
First CM&D product acquisition will be in the $800 million worldwide market for hyperphosphataemia
16 January 2008: CM&D Pharma and Natreon Inc announce the incorporation of Puredel Ltd to develop oral insulin
Oral insulin compound is subject of major joint venture between CM&D Pharma and Natreon Inc.
31 October 2007: Successful £500,000 Initial Fund Raising By CM&D Pharma Ltd
CM&D Raises £0.5 million to fund acquisition of core product and technology portfolio
22 October 2007: Dr Christian Weber, VP Business Development, Hospira, is Appointed to CM&D Advisory Board
CM&D Pharma has made the first appointment to its Advisory Board. He is Dr Christian Weber, currently Head of Business Development for Hospira Inc in Europe.
15 October 2007: CM&D Pharma Expands to New Offices
The rapid growth of CM&D Pharma has meant re-location of its Headquarters
08 October 2007: CM&D Pharma Appoints Dr Maria Cristina Comelli as R&D Project Leader
CM&D Pharma further strengthens its core management team by appointing Dr Comelli to spearhead its R&D programme.
01 October 2007: Jeremy King Appointed as Non-Executive Director
CM&D is preparing for rapid growth by appointing a senior corporate finance executive as Non-Executive Director.
01 September 2007: CM&D Pharma Limited A New Concept in Concerted Marketing and Development Launched
CM&D Pharma is a new European niche hospital products company, created by Danilo Casadei Massari
|
